NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free BNTX Stock Alerts $92.97 +1.27 (+1.38%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$90.80▼$93.5650-Day Range$88.96▼$100.2952-Week Range$85.21▼$131.52Volume378,014 shsAverage Volume697,110 shsMarket Capitalization$22.10 billionP/E Ratio22.57Dividend YieldN/APrice Target$133.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside29.5% Upside$120.40 Price TargetShort InterestBearish1.30% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.16Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.00) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.85 out of 5 starsMedical Sector486th out of 939 stocksBiological Products, Except Diagnostic Industry76th out of 151 stocks 4.2 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $120.40, BioNTech has a forecasted upside of 29.5% from its current price of $92.97.Amount of Analyst CoverageBioNTech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.30% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in BioNTech has recently increased by 5.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.8 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BioNTech is 37.14%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 1.6 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for BioNTech this week, compared to 9 articles on an average week.Search Interest36 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat FollowsOnly 54 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease in the coming year, from ($1.00) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 22.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.11.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 22.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 255.14.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Lowered to $101.00 at UBS GroupMarch 26, 2024 | investorplace.com3 Biotech Stocks to Buy for the Next Bull Run: March 2024March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 26, 2024 | finance.yahoo.comThis Vaccine Maker Sits on Cash Almost Equal to Its Market ValueMarch 25, 2024 | markets.businessinsider.comOptimistic Outlook for BioNTech: A Buy Rating Amidst Vaccine Demand and Strong Oncology PipelineMarch 24, 2024 | finance.yahoo.comBioNTech Full Year 2023 Earnings: Misses ExpectationsMarch 23, 2024 | finance.yahoo.comEarnings Miss: BioNTech SE Missed EPS By 14% And Analysts Are Revising Their ForecastsMarch 23, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) PT Lowered to $90.00 at JPMorgan Chase & Co.March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 23, 2024 | americanbankingnews.comCanaccord Genuity Group Reiterates Buy Rating for BioNTech (NASDAQ:BNTX)March 22, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Cut to $123.00 by Analysts at BMO Capital MarketsMarch 22, 2024 | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of "Hold" from AnalystsMarch 22, 2024 | msn.comBioNTech Tumbles as Q4 Profit, Sales Trail Estimates on Falling COVID-19 Vaccine DemandMarch 21, 2024 | msn.comWhy Is BioNTech Stock Trading Lower On Wednesday?March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Edwards Lifesciences (EW) and Innovent Biologics (OtherIVBXF)March 21, 2024 | markets.businessinsider.comHold Rating for BioNTech: Navigating Vaccine Revenue Decline and Prospective Oncology PipelineMarch 21, 2024 | finance.yahoo.comBioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comMaintaining Hold on BioNTech: A Balancing Act Between Near-Term Challenges and Long-Term Oncology InvestmentMarch 20, 2024 | msn.comBioNTech slides as earnings plunge amid cancer drug shiftMarch 20, 2024 | seekingalpha.comPfizer partner BioNTech ekes out Q4 profit despite 65% revenue dropMarch 20, 2024 | finance.yahoo.comBioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter FinancialsMarch 20, 2024 | rttnews.comBioNTech Q4 Net Profit Plummets March 20, 2024 | seekingalpha.comBioNTech's Brew: Mixing COVID Legacy With Oncology AmbitionsMarch 20, 2024 | investorplace.comBNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023March 20, 2024 | barrons.comBioNTech Earnings Fall Short of Estimates. The Stock Is Down.March 20, 2024 | finanznachrichten.deBioNTech SE: BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateMarch 20, 2024 | reuters.comAfter earnings plunge, BioNTech pins hopes on cancer drug launchesSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$120.40 High Stock Price Target$171.00 Low Stock Price Target$90.00 Potential Upside/Downside+43.9%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$4.12 Trailing P/E Ratio22.57 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins24.26% Pretax Margin31.06% Return on Equity4.60% Return on Assets4.12% Debt Debt-to-Equity Ratio0.01 Current Ratio9.43 Quick Ratio9.26 Sales & Book Value Annual Sales$3.82 billion Price / Sales5.79 Cash Flow$5.07 per share Price / Cash Flow18.34 Book Value$92.17 per share Price / Book1.01Miscellaneous Outstanding Shares237,726,000Free Float192,083,000Market Cap$22.10 billion OptionableOptionable Beta0.23 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $895.64kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $943.18kDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $990.72kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $478.61kMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $918.33kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Mr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Oliver Henning Ph.D.Senior Vice President of OperationsDr. Sebastian Kreiter M.D.Senior Vice President of Immunotherapy & Preclinical ResearchMr. Siegbert KloosSenior Vice President of Global R&D Digital, Datand InformaticsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBiogenNASDAQ:BIIBBio-TechneNASDAQ:TECHRepligenNASDAQ:RGENView All CompetitorsInstitutional OwnershipPNC Financial Services Group Inc.Bought 1,743 shares on 3/22/2024Ownership: 0.001%Goldman Sachs Group Inc.Bought 26,777 shares on 3/1/2024Ownership: 0.077%Investmentaktiengesellschaft Fuer Langfristige Investoren TGVBought 3,000 shares on 3/1/2024Ownership: 0.006%Quintet Private Bank Europe S.A.Sold 440 shares on 2/29/2024Ownership: 0.000%Virtu Financial LLCBought 2,600 shares on 2/26/2024Ownership: 0.001%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BioNTech was last updated on Sunday, March 24, 2024 at 3:10 PM. Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech has a growing pipeline of drugs, including advanced oncology programs with multiple trials in progress. This diversification reduces dependency on any single product or market segment, potentially mitigating risks associated with a narrow product portfolio. The company's stock price has shown resilience and potential for growth, with a current valuation that presents a value opportunity for investors compared to industry averages. This could indicate a favorable entry point for those seeking long-term growth potential. Recent developments, such as the launch of innovative mRNA vaccine candidates like the Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine, demonstrate BioNTech's commitment to addressing evolving healthcare needs and staying at the forefront of biopharmaceutical innovation. BioNTech's expansion of its pipeline to include various modalities and promising candidates in advanced clinical trials positions the company as an attractive target for potential partnerships or acquisitions by larger pharmaceutical firms seeking to bolster their portfolios and address upcoming patent cliffs. The company's CEO, Prof. Ugur Sahin, highlighted significant progress in advancing the pipeline and achieving positive clinical data in various programs, indicating a strong leadership focus on innovation and growth in the biotechnology sector. Cons Investors should be bearish about investing in BioNTech SE for these reasons: While BioNTech's pipeline expansion is promising, the biopharmaceutical industry is highly competitive and subject to regulatory uncertainties, clinical trial outcomes, and market dynamics that could impact the company's future growth prospects and financial performance. The potential for regulatory challenges or delays in the approval process for new drug candidates could introduce uncertainties and risks to BioNTech's revenue projections and market positioning, affecting investor sentiment and stock performance. Market volatility and macroeconomic factors, such as shifts in healthcare policies, global health crises, or changes in investor sentiment towards biotechnology stocks, may influence BioNTech's stock price and overall market performance, leading to fluctuations in investment returns. BioNTech's dependence on successful clinical trials, regulatory approvals, and commercialization of new products for revenue growth exposes the company to inherent risks associated with drug development, including potential setbacks, competition, and market acceptance challenges. Investors should consider the company's debt-to-equity ratio, liquidity position, and overall financial health when evaluating investment opportunities, as these factors can impact BioNTech's ability to fund research and development initiatives, expand operations, and navigate industry challenges. BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 10 Wall Street research analysts have issued 1-year price targets for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they anticipate the company's stock price to reach $120.40 in the next year. This suggests a possible upside of 29.5% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2024? BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX stock has decreased by 11.9% and is now trading at $92.97. View the best growth stocks for 2024 here. Are investors shorting BioNTech? BioNTech saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,080,000 shares, an increase of 5.5% from the February 29th total of 2,920,000 shares. Based on an average daily trading volume, of 689,800 shares, the days-to-cover ratio is currently 4.5 days. Currently, 1.3% of the company's shares are sold short. View BioNTech's Short Interest. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) released its quarterly earnings results on Monday, November, 6th. The company reported $0.67 EPS for the quarter, beating the consensus estimate of ($0.59) by $1.26. The firm earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech had a trailing twelve-month return on equity of 4.60% and a net margin of 24.26%. BioNTech's quarterly revenue was down 74.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $7.04 EPS. Is BioNTech a good dividend stock? BioNTech (NASDAQ:BNTX) pays an annual dividend of $1.53 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 37.14%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for BNTX. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB). What guidance has BioNTech issued on next quarter's earnings? BioNTech updated its FY 2024 earnings guidance on Tuesday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $4.2 billion. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.66%), Primecap Management Co. CA (2.00%), Harding Loevner LP (1.66%), Flossbach Von Storch AG (1.49%), Capital World Investors (0.39%) and Voloridge Investment Management LLC (0.25%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.